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A number of guidelines on the conduct of clinical
trials in osteoarthritis (OA) have been published in
recent years [1–3]. Such guidelines are useful in
suggesting, amongst others: appropriate case
definitions, inclusion and exclusion criteria and
outcome measures. These guidelines can be used in
trials of drugs that may modify symptoms and/or
structural change. Such consensus statements
should encourage more thoughtful, more consist-
ent and hopefully better study designs. Greater
homogeneity also permits wider inclusion of study
data within systematic reviews and meta-analyses.
A number of practical and theoretical issues still
need to be addressed, and subjected to wider
discussion. Particularly important we feel are
those which may adversely affect patient recruit-
ment, drop-out rate, and generalizability of study
findings. We believe that the following aspects of
knee OA drug clinical trials, in particular, require
further debate.
Should only one (signal) joint receive
treatment and/or assessment?
In rheumatoid arthritis (RA) information on
many joints is pooled to give a single summated
score for one individual, expressed, for example, as
the swollen joint count or tender joint count [4].
Pain scores in RA are also given as a single overall
score with no reference to a specified ‘signal’ or
worst joint [4].
By contrast, in OA studies the primary outcome
assessment is inevitably focused on a single joint
site, specifically the knee, hip or hand [1, 2]. This
appears reasonable in that:
(1) Risk factors for development and progression
of OA are site specific so that focus on one site
encourages homogeneity of the study popu-
lation,
(2) Unlike RA, OA usually causes symptoms at just
one or a few sites at any particular time.
However, the majority of patients with knee or
hand OA, and many patients with hip OA, have
bilateral symptoms. In these cases, it is advised
that the most symptomatic knee or hip is selected
as the signal joint for symptom-modifying studies
[1, 2]. Assessment of the contralateral joint can be
included as a secondary outcome measure [1]. For
hands, however, it is apparently acceptable to pool
data from right and left sides, although more
attention might be given to the dominant side [1].
This approach presents several practical and
theoretical problems with respect both to assess-
ment and drug treatment. For example:
, Many patients report that both knees are
equally symptomatic, or that the ‘worst’ knee
changes from week to week. Should such
patients be excluded from study? Should one
knee be picked at random as the signal joint?
Should both knees receive equal treatments and
be assessed equally for outcome? The latter
option would facilitate recruitment to studies
and also produce more generalizable data that
reflects clinical practice—how many physicians
would treat just one of two symptomatic knees?
, Many patients find it hard to give separate
scores for pain and function for bilaterally
symptomatic knees. Pain experience on one side
may influence pain reporting on the other [5].
There are no data to suggest that pain severity
is halved if one rather than two equally
troublesome knees are involved. A composite
(right and left) knee pain assessment would
fairly represent the pain severity experienced by
an individual.
, If intra-articular treatment is given to just one
knee, exacerbation of pain in the contralateral
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untreated knee during the study period may
result in patient withdrawal irrespective of the
effect of treatment on the signal knee. This
necessitates inclusion of additional patients in
trials. If both symptomatic knees were given the
same treatment (active or placebo) this would
hopefully decrease the drop-out rate, and might
reduce the numbers of patients required for study.
, If comparison is being made between an oral
analgesic drug (which may benefit both knees)
and an intraarticular drug/device (which will
solely or predominantly influence just one knee)
there could be bias in favour of the oral
compound. Equal intra-articular treatment of
both knees would redress this bias.
, Is it rational to recommend a pooled index for
the small joints of one or both hands but not for
both knees or both hips? Each knee has three
compartments that may contribute to intracap-
sular pain, so that pooling of information on one
knee has already occurred.
, Symptom causation in knee OA may result from
various mechanisms. Should we aim for consist-
ency, at least in differentiating intracapsular
from periarticular pain through simple examin-
ation techniques?
Inclusion of two symptomatic knees (or hips) in
assessment and in treatment could, therefore:
facilitate recruitment; reduce drop-out rates;
eliminate certain bias in between treatment com-
parisons; and produce more generalizable, ‘real
world’ treatment data. Stratification for one or two
joint involvement could easily be included in
randomization. Intra-articular treatments should
obviously be the same (treatment or placebo) for
the two knees. Because multiple joints from one
subject cannot be treated as independent variables
(‘two knees, one person’ consideration [6, 7])
outcomes would need either to be expressed as a
single score for one individual, or more complex
analytical techniques are required [6, 7]. If data is
pooled, this might involve: use of single patient
responses for pain and function for both knees in
disease-specific instruments (eg the WOMAC or
Lesquesne index [1]); assessments could be under-
taken for both sides and then pooled into a single
mean score, or a joint chosen at random. For more
generic arthritis, health status and quality of
life/utility instruments laterality is not an issue.
Should there be restricted radiographic entry
criteria?
It is clearly reasonable to require definite
radiographic change at the site of interest to
confirm a diagnosis of structural ‘OA’ [1, 2].
However, marked structural change on X-ray is
regarded as an exclusion for clinical trials of knee
or hip OA [1, 2], and at the knee the (medial)
tibiofemoral compartment is often given sole
prominence with no consideration of the patello-
femoral compartment [1].
It is clearly important to select patients with
mild–moderate radiographic change for study of
structure modifying drugs, so that progression of
joint space narrowing can be assessed. For
symptom modifying drugs the situation is different.
The frequent discordance between X-ray changes
and symptoms in OA, even at the knee and hip, is
well recognized [8]. The premise that inclusion of
severe structural OA is an unfair test of
symptom-modifying drugs [2] requires testing.
Furthermore, the patello-femoral compartment is a
common target site for OA and probably a common
site for symptom causation [10]. Studies that focus
solely on anteroposterior tibiofemoral X-rays may
in fact be including patients with severe
patellofemoral structural change, even though
they are selecting for mild–moderate tibiofemoral
OA. If the primary outcome measure is pain,
assessed over a period as short as four months,
should we unduly worry about the degree or
location of X-ray change? Such restriction limits
recruitment, especially from hospital-based clinics.
Furthermore, data are produced that relate only to
mild–modest structural OA, reducing their gener-
alizability to the OA population. Inclusion of any
X-ray grade, with assessment of all three knee
compartments, would increase recruitment and the
generalizability of the study data. Severity and
location of radiographic change might then be
examined as a possible predictor of response. We
would favour a broad rather than narrow
definition of patient radiographic eligibility [1].
The most important entry criterion, and primary
outcome measure, for studies of symptom-modify-
ing drugs should be the level of reported pain.
Although the lower limit required is defined
( r 25 mm on a 100 mm visual analogue scale, or
r 1 on a 5 point categorical scale [1]), the upper
limit also requires definition—very high pain
scores are biased to change only in a downward
direction towards improvement. We would favor
entry levels in the range of r 25– R 75 mm (100 mm
visual analogue scale), or r 1– R 4 (5 point ordinal
scale).
How should study results be expressed?
Current guidelines are careful not to define a
minimum clinically important response in
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symptom-modifying drug trials. Although some
investigators do give their own definition of a
positive clinical response (often an improvement of
q 20 mm on a 100 mm visual analogue pain
scale—the same effect size that is often used in
power calculations) variability in definitions and
outcome measures impedes comparison between
studies. In the absence of response criteria, study
results are usually expressed as relative benefit of
the treatment group compared to the placebo
group (i.e., comparisons of means or medians).
However, even if the mean difference between a
treatment and a control group is less than the
smallest change that is considered important, the
treatment could have had an important impact on
many of the study patients. For this reason it is an
advantage to express results also in terms of the
‘number needed to treat’ to obtain good benefit
[10, 11]. Despite certain caveats, agreed site-
specific response criteria for symptom relief of OA
would greatly facilitate such reporting and assist
between study comparisons of effect size of
treatments.
In line with other biomedical journals, editors
of most rheumatology journals now conform to
the CONSORT (Consolidation of Standards for
Reporting Trials) format for the reporting of
clinical trials [12]. This requires explicit details
on all important aspects of a randomized con-
trolled trial. If adhered to, such presentation will
enable the data to be appropriately judged. It will
also encourage good quality scores (13) and
inclusion of the data in any systematic review.
Guidelines on OA studies should support such
presentation.
These and other practical issues require contin-
uing discussion. There is no single correct
approach but Osteoarthritis and Cartilage is an
ideal forum for such debate. Guidelines are never
set in stone and regular review and revision is part
of the undertaking of the groups that publish them.
The participation of those that will have to
implement them is vital in this process.
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